The arrival of Retatrutide ZPHC, at a strength of 120mg, is creating considerable interest within the healthcare community. This innovative dual GIP and GLP-1 receptor medication suggests to deliver significant improvements in weight shedding compared to existing therapies. Initial clinical trial